Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Acute myeloid leukemia
Menin inhibitors, FLT3 and IDH combinations, venetoclax backbones and what comes after.
SITC Annual Meeting 2026
4–8 Nov 2026, Phoenix · Journal for ImmunoTherapy of Cancer 14 (Suppl 2 and 3), open access
1,109 regular and 19 late-breaking abstracts are in Crossref as open-access JITC supplement records (CC BY-NC); the supplement may still be filling in.
Indexed in Crossref
5 abstracts matching acute myeloid leukemia from the meeting's journal supplement, fetched live from Crossref 2026-11-12 08:27 UTC. This is a keyword search, not the complete abstract book.
- 1065Trispecific CD117/CD33 targeting and CD16a engaging antibody depletes malignant clones in high-risk acute myeloid leukemia and myelodysplastic syndromeParveen Shiraz, Carlos J Rodriguez Santiago, Sonia M Fonseca, Kathy P Le et al.
- 466CAMV-01 targets VIP signaling, a novel immune checkpoint pathway, for the treatment of acute myeloid leukemiaAntonio Ward, Swapnaa Balaji, Maryam Azeem, Jian-Ming Li et al.
- 918Base-edited knockout of MED12, ARIH2, CCNC, or UBE2F in primary NK cells enhanced CD122 and NKG2D expression as well as cytotoxicity against acute myeloid leukemiaMorgan Anderson-Crannage, Hao Yu, Yanling Liao, Mishel Ramirez et al.
- 1058Dual antigen targeting TriKE-PACCs enhance NK cell function and anti-leukemic activity against AMLAnders W Matson, Caden Caligiuri, Katherine Koehler, Behiye Kodal et al.
- 1042Optimization of CD3 engagement improves T-cell fitness while preserving potent antileukemic activity of the PS/Man9-targeted trispecific T-cell engager hcVTRU200 in AMLManpreet Bariana, Shabnam Samimi, Megan Lloren, Shaina Anuncio et al.